Publications in OpenAlex of which a co-author is affiliated to this organization
All publications | By field | By subfield
All publications [Next]
| Title | DOI |
|---|---|
| https://doi.org/10.1038/nrclinonc.2015.169 | Drug repurposing in oncology—patient and health systems opportunities |
| https://doi.org/10.3332/ecancer.2017.781 | Repurposing Drugs in Oncology (ReDO)—chloroquine and hydroxychloroquine as anti-cancer agents |
| https://doi.org/10.3332/ecancer.2014.485 | Repurposing drugs in oncology (ReDO)—Cimetidine as an anti-cancer agent |
| https://doi.org/10.1186/s13023-019-1075-8 | Information needs of physicians regarding the diagnosis of rare diseases: a questionnaire-based study in Belgium |
| https://doi.org/10.3332/ecancer.2015.521 | Repurposing Drugs in Oncology (ReDO)—itraconazole as an anti-cancer agent |
| https://doi.org/10.3332/ecancer.2018.886 | ReDO_DB: the repurposing drugs in oncology database |
| https://doi.org/10.3332/ecancer.2016.610 | Repurposing Drugs in Oncology (ReDO)—diclofenac as an anti-cancer agent |
| https://doi.org/10.3332/ecancer.2016.680 | Repurposing Drugs in Oncology (ReDO)—Propranolol as an anti-cancer agent |
| https://doi.org/10.3332/ecancer.2015.513 | Repurposing Drugs in Oncology (ReDO)—clarithromycin as an anti-cancer agent |
| https://doi.org/10.3389/fphar.2019.01664 | On-Label or Off-Label? Overcoming Regulatory and Financial Barriers to Bring Repurposed Medicines to Cancer Patients |
| https://doi.org/10.1093/noajnl/vdab075 | A phase Ib/IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma: CUSP9v3 |
| https://doi.org/10.1016/j.semcancer.2020.01.008 | Repurposing drugs in oncology: From candidate selection to clinical adoption |
| https://doi.org/10.3389/fphar.2018.00637 | “Hard” Drug Repurposing for Precision Oncology: The Missing Link? |
| https://doi.org/10.3389/fphar.2021.627574 | An Open Access Database of Licensed Cancer Drugs |
| https://doi.org/10.1007/s00262-022-03253-x | Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: Results of the phase II PRIMMO study |
| https://doi.org/10.1016/j.jcpo.2022.100375 | Cancer literacy – Informing patients and implementing shared decision making |
| https://doi.org/10.1186/s12943-025-02365-z | Targeting metastasis in paediatric bone sarcomas |
| https://doi.org/10.3390/cancers17010059 | Synergistic Potential of Antibiotics with Cancer Treatments |
| https://doi.org/10.1016/j.eclinm.2025.103203 | Genetic predisposition in sarcomas: clinical implications and management |
| https://doi.org/10.1016/j.trecan.2017.06.007 | Repurposing Drugs in Oncology: Next Steps |
| https://doi.org/10.1186/s12885-019-5676-3 | PRIMMO study protocol: a phase II study combining PD-1 blockade, radiation and immunomodulation to tackle cervical and uterine cancer |
| https://doi.org/10.3332/ecancer.2015.568 | Repurposing Drugs in Oncology (ReDO)—nitroglycerin as an anti-cancer agent |
| https://doi.org/10.3332/ecancer.2018.824 | Repurposing drugs in oncology (ReDO)—selective PDE5 inhibitors as |
| https://doi.org/10.2217/fon.14.244 | Repurposing drugs in your medicine cabinet: untapped opportunities for cancer therapy? |
| https://doi.org/10.3389/fnut.2018.00138 | A Phase 2 Study to Assess the Immunomodulatory Capacity of a Lecithin-based Delivery System of Curcumin in Endometrial Cancer |
| https://doi.org/10.1186/s13063-021-05273-x | Exploring new uses for existing drugs: innovative mechanisms to fund independent clinical research |
| https://doi.org/10.1136/bmj.k2701 | New uses for old drugs |
| https://doi.org/10.3389/fonc.2021.688755 | Repurposing Infectious Diseases Vaccines Against Cancer |
| https://doi.org/10.1016/s1470-2045(18)30076-7 | Cancer groundshot: going global before going to the moon |
| https://doi.org/10.2217/fon-2019-0233 | Journal Retractions in Oncology: A Bibliometric Study |
| https://doi.org/10.1038/s43018-020-0030-x | Challenges and opportunities for cancer clinical trials in low- and middle-income countries |
| https://doi.org/10.3332/ecancer.2015.ed50 | The wisdom of crowds and the repurposing of artesunate as an anticancer drug |
| https://doi.org/10.1038/nrclinonc.2017.69 | Scientific advice — is drug repurposing missing a trick? |
| https://doi.org/10.4149/neo_2019_190110n34 | Evidence of β-blockers drug repurposing for the treatment of triple negative breast cancer: A systematic review |
| https://doi.org/10.1080/2162402x.2015.1049802 | Cryoablation and Meriva have strong therapeutic effect on triple-negative breast cancer |
| https://doi.org/10.1136/jitc-2020-001250 | Nicotinamide combined with gemcitabine is an immunomodulatory therapy that restrains pancreatic cancer in mice |
| https://doi.org/10.3389/fphar.2021.790952 | A Database of Drug Repurposing Clinical Trials in Oncology |
| https://doi.org/10.1200/go.20.00591 | Trends in International Cancer Research Investment 2006-2018 |
| https://doi.org/10.1371/journal.pone.0225748 | Intraoperative ketorolac in high-risk breast cancer patients. A prospective, randomized, placebo-controlled clinical trial |
| https://doi.org/10.3389/fmed.2021.817663 | Repurposing of Medicines in the EU: Launch of a Pilot Framework |
| https://doi.org/10.1080/0284186x.2021.1953136 | Use of non-cancer drugs and survival among patients with pancreatic adenocarcinoma: a nationwide registry-based study in Norway |
| https://doi.org/10.3389/fphar.2022.960701 | How to balance valuable innovation with affordable access to medicines in Belgium? |
| https://doi.org/10.1158/1078-0432.ccr-24-0101 | Biological Sample Collection to Advance Research and Treatment: A Fight Osteosarcoma Through European Research and Euro Ewing Consortium Statement |
| https://doi.org/10.1016/j.annonc.2023.05.006 | Patient-centered, self-funding dose optimization trials as a route to reduce toxicity, lower cost, and improve access to cancer therapy |
| https://doi.org/10.1016/j.ygyno.2024.10.020 | Associations of the gut microbiome with outcomes in cervical and endometrial cancer patients treated with pembrolizumab: Insights from the phase II PRIMMO trial |
| https://doi.org/10.1016/j.ctrv.2025.103003 | How to foster new treatment development in ultra-rare tumours? Joint EMA-EORTC multi-stakeholder workshops on ultra-rare sarcomas as a model for rare cancers |
| https://doi.org/10.3389/fonc.2024.1367237 | The patient perspective on sirolimus for epithelioid hemangioendothelioma (EHE): results of a community survey highlighting the importance of equitable access to treatments |
| https://doi.org/10.1001/jamaoncol.2025.5376 | Enhancing Clinical Cancer Research Through Sharing of Data and Biospecimens |
| https://doi.org/10.3332/ecancer.2020.1071 | Repurposing of drugs for triple negative breast cancer: an overview |
| https://doi.org/10.3389/fonc.2019.01408 | Anakoinosis: Correcting Aberrant Homeostasis of Cancer Tissue—Going Beyond Apoptosis Induction |
| https://doi.org/10.3332/ecancer.2015.541 | Primed for cancer: Li Fraumeni Syndrome and the pre-cancerous niche |
| https://doi.org/10.3332/ecancer.2016.689 | Next generation metronomic chemotherapy—report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6–8 May 2016, Mumbai |
| https://doi.org/10.1016/j.ejso.2017.08.010 | Perioperative therapies – Enhancing the impact of cancer surgery with repurposed drugs |
| https://doi.org/10.1080/21678707.2018.1500690 | Omics-driven drug repurposing as a source of innovative therapies in rare cancers |
| https://doi.org/10.1186/s13613-021-00925-2 | High mean arterial pressure target to improve sepsis-associated acute kidney injury in patients with prior hypertension: a feasibility study |
| https://doi.org/10.1200/go.22.00233 | European Cancer Organisation's Inequalities Network: Putting Cancer Inequalities on the European Policy Map |
| https://doi.org/10.3332/ecancer.2018.ed76 | Does the oncology community have a rejection bias when it comes to repurposed drugs? |
| https://doi.org/10.1016/s1470-2045(23)00070-0 | Access to new drugs in paediatric oncology: can we learn from the ongoing ONC201 saga? |
| https://doi.org/10.3390/cancers15072020 | Phase I Study of a Combination of Fluvastatin and Celecoxib in Children with Relapsing/Refractory Low-Grade or High-Grade Glioma (FLUVABREX) |
| https://doi.org/10.3390/cancers14071621 | Inhibiting the Priming for Cancer in Li-Fraumeni Syndrome |
| https://doi.org/10.1136/ijgc-2022-003585 | Drug repurposing as a potential source of innovative therapies in cervical cancer |
| https://doi.org/10.1200/po-25-00377 | Recurrent and Refractory Ewing Sarcoma Phase I/II Trials: Current Perspective From the Euro-Ewing Consortium |
| https://doi.org/10.1111/bph.70243 | The eyes of the beholder: Perceived barriers to successful drug repurposing |
| https://doi.org/10.3389/fmed.2020.00033 | Sharing of Clinical Trial Data and Samples: The Cancer Patient Perspective |
| https://doi.org/10.3389/fphar.2021.599598 | A Randomized Phase II Trial Comparing the Efficacy and Safety of Pioglitazone, Clarithromycin and Metronomic Low-Dose Chemotherapy with Single-Agent Nivolumab Therapy in Patients with Advanced Non-small Cell Lung Cancer Treated in Second or Further Line (ModuLung) |
| https://doi.org/10.1136/bmjopen-2020-040406 | Pancreatic resection with perioperative drug repurposing of propranolol and etodolac: trial protocol of the phase-II randomised placebo controlled PROSPER trial |
| https://doi.org/10.3389/fphar.2019.00287 | A Computational Model of Tumor Growth and Anakoinosis |
| https://doi.org/10.1016/j.ejca.2021.03.013 | The European Union and personalised cancer medicine |
| https://doi.org/10.1016/b978-0-12-819668-7.00001-4 | Drug repurposing for cancer therapy—an introduction |
| https://doi.org/10.1016/s0140-6736(23)00633-5 | Drug evidence watch: a process to the benefit of public health |
| https://doi.org/10.1016/s1470-2045(20)30561-1 | Drug repurposing in oncology |
| https://doi.org/10.1016/j.ejca.2024.114003 | How to develop new systemic treatments in ultra-rare cancers with high unmet needs? The case of alveolar soft-part sarcoma |
| https://doi.org/10.1016/s1470-2045(25)00037-3 | Determining the optimal use of approved drugs in oncology |
| https://doi.org/10.1016/j.hoc.2025.04.008 | Approaches to Ultra-Rare Sarcomas |
| https://doi.org/10.1016/j.ijgc.2025.102849 | Increased hospital case volume is associated with improved survival and quality of care for uterine corpus cancer in Belgium |
| https://doi.org/10.1007/s00262-014-1587-y | Inconsistencies and questionable reliability of the publication “Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophages-activating, GcMAF” by Yamamoto et al |
| https://doi.org/10.3332/ecancer.2019.982 | Is there any benefit to particles over photon radiotherapy? |
| https://doi.org/10.3390/cancers15030769 | Exploiting the Stemness and Chemoresistance Transcriptome of Ewing Sarcoma to Identify Candidate Therapeutic Targets and Drug-Repurposing Candidates |
| https://doi.org/10.1177/1073110519876182 | Lung Cancer Survival Gains: Contributions of Academia and Industry |
| https://doi.org/10.1186/s12885-022-09671-5 | Completeness and selection bias of a Belgian multidisciplinary, registration-based study on the EFFectiveness and quality of Endometrial Cancer Treatment (EFFECT) |
| https://doi.org/10.1371/journal.pone.0274115 | Diminishing clinical impact for post-approval cancer clinical trials: A retrospective cohort study |
| https://doi.org/10.1016/j.ygyno.2023.11.015 | Practice patterns, time trends and quality of care of uterine cancer in Belgium: An analysis of the EFFECT database |
| https://doi.org/10.1093/annonc/mdx658.006 | Repurposing non-cancer drugs in oncology: Aspirin and metformin are only the tip of the iceberg |
| https://doi.org/10.2147/cmar.s483151 | Drug Repurposing in Pancreatic Cancer: A Multi-Stakeholder Perspective to Improve Treatment Options for Pancreatic Cancer Patients |
| https://doi.org/10.1016/j.jval.2024.10.1581 | HPR155 Drug Repurposing: Policy Barriers to Using Existing Pharmaceuticals in New Indications: Results of a Systematic Literature Review |
| https://doi.org/10.1016/j.breast.2025.104642 | The Breast International Group (BIG) Patient Partnership: Embedding meaningful patient involvement in the design and conduct of breast cancer clinical research |
| https://doi.org/10.1016/j.hpopen.2026.100168 | Policy barriers to drug repurposing in Europe: different stakeholder perspectives identified during survey-based shortlisting of key challenges |
| https://doi.org/10.1097/ppo.0000000000000361 | Perioperative Therapies—Using Repurposed Drugs to Improve Cancer Surgery Outcomes |
| https://doi.org/10.1016/s1470-2045(21)00009-7 | Diffuse intrinsic pontine glioma: a clinic in Mexico, social media, and unpublishable data |
| https://doi.org/10.1038/s41571-022-00646-w | Ensuring completeness and timeliness of cancer treatment guidelines |
| https://doi.org/10.2217/fon-2019-0763 | Biased by design? Clinical trials and patient benefit in oncology |
| https://doi.org/10.1038/550188a | Tap latent source of frugal cancer ideas |
| https://doi.org/10.1093/neuonc/noaa222.134 | EPCT-11. PHASE 1 STUDY OF FLUVASTATIN-CELECOXIB COMBINATION IN CHILDREN WITH RELAPSING/REFRACTORY OPTICO-CHIASMATIC LOW-GRADE GLIOMA OR HIGH-GRADE GLIOMAS (FLUVABREX): FINAL RESULTS |
| https://doi.org/10.1136/ijgc-2022-esgo.401 | 2022-RA-638-ESGO Pembrolizumab with multimodal immunomodulation in chemotherapy-pretreated cervical, endometrial, and uterine cancer: the PRIMMO phase II trial |
| https://doi.org/10.1016/j.pan.2018.05.159 | Drug repurposing as a source of innovative therapies in pancreatic cancer |
| https://doi.org/10.1016/j.annonc.2021.10.178 | 159P Pembrolizumab, SBRT, and immunomodulation for recurrent and/or refractory cervical or endometrial carcinoma |
| https://doi.org/10.3332/ecancer.2014.463 | ecancermedicalscience |
| https://doi.org/10.3332/ecancer.2014.442 | ecancermedicalscience |
| https://doi.org/10.3332/ecancer.2018.ed82 | Propranolol and breast cancer—a work in progress |
| https://doi.org/10.1101/197434 | Repurposing non-cancer Drugs in Oncology – How many drugs are out there? |